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Abstract : In the present study involving
patients with bone metastases arising from
prostate cancer, we measured urinary
deoxypyridinoline (DPD) as a marker of
collagen breakdown activity, serum total and
bone-specific alkaline phosphatase activities
and serum prostate specific antigen (PSA).
This study included 20 patients with benign
prostate hyperplasia (BPH) and 23 patients
with carcinoma, 11 of had with bone
metastases. DPD excretion in urine was
significantly greater in prostate cancer
patients with bone metastasis than in those
with localised prostate cancer or BPH
(p<0.001), but the difference between the
localised prostate cancer and BPH groups was
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Introduction
Prostate cancer commonly causes osteoblastic
metastases, which present problems in treating patients
with advanced prostate cancer. PSA is widely accepted as
the most important marker for detecting prostate cancer
and for monitoring treatment (1). However, it has a low
positive predictive value for bone metastases (2).
Tumours infiltrating bone produce simultaneous bone
destruction and reactive bone formation. Biochemical
markers of bone metabolism have been studied as
indicators of bone response, including urinary calcium
(3), urinary hydroxyproline (4) and serum ALP (5), all of
which are influenced by the rate of bone resorption.
However, they are somewhat limited for routine clinical
evaluation. New markers for bone metastasis are
required in order to evaluate the activity and response of
bone metastases of prostate cancer. When the bone
matrix is resorbed, the cross-link residues, pyridinoline
and DPD are released from the collagen molecules and
eventually excreted in urine (6). Several reports suggest
that the assay of these collagen cross-link residues may
provide valuable markers of bone metastases in patients
with prostate cancer (7) or breast cancer (8). In the

not significant (p>0.05). The serum markers
of bone formation [total alkaline phosphatase
(T-ALP) and bone ALP (B-ALP)] displayed
higher mean concentrations in the group with
positive bone metastases than in the group
with local disease (p<0.001 for both). Serum
T-ALP and B-ALP levels and urinary excretion
of DPD were significantly correlated with the
Soloway score (p=0.03, p=0.01 and p=0.01
respectively). Urinary DPD and serum B-ALP
and T- ALP may provide useful information
for supplementing PSA and bone-scan results
in evaluating bone-metastatic activity.
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present study involving patients with bone metastases
arising from prostate cancer, we measured urinary DPD
as a marker of collagen breakdown activity, serum total
and bone-specific alkaline phosphatase activities and
serum PSA. The aim of the study was to investigate the
relationship of these parameters and to determine the
association between DPD and neoplastic bone
involvement in patients with prostate cancer.

Materials and Methods
This study included 20 patients with BPH and 23
patients with prostate carcinoma, 11 of whom had bone
metastases. BPH was documented pathologically by
prostate biopsy or transurethral resection. Patients with
localised prostate cancer were found to have normal
pelvic lymph nodes by computerised tomography, and
normal results in bone scintigraphy. Localised cancer
patients were treated with radiotherapy or radical
prostatectomy, and metastatic cancer patients with
hormonotheraphy. Diagnosis of bone involvement was
performed with bone scintigraphy followed by
radiological confirmation. Exclusion criteria were as
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follows: any history of recent bone fracture, history of a
second primary cancer or metabolic bone disease, current
use of corticosteroids and any liver disease or other
bone diseases leading to increases in ALP. All samples
were drawn in the early morning after an overnight fast,
and included spot urine specimens for measurement of
creatinine and DPD, and blood specimens for
measurements of PSA, T-ALP and B-ALP. The serum and
urine specimens obtained were stored at –70ºC until the
assay date. Urine DPD and serum PSA were measured by
chemiluminescence (Immulite), and serum ALP and urine
creatinine were measured with commercially available kits
(Boehringer Mannheim, Germany). The expected values
for DPD in man are 2.3-5.4 nM DPD/mM creatinine. In BALP, after the total activity of ALP was determined, boneALP was precipitated using the precipitant_a lectin from
wheat germ_and the remaining ALP activity measured in
the supernatant.
Bone scintigram metastatic burden was graded and
patients were divided into 4 groups as described
previously by Soloway et al. (9). The scans were graded
as follows 1) less than 6 bony metastases each of which
was less than 50% the size of a vertebral body (a lesion
occupying the entire vertebral body was counted as 2
lesions); 2) 6 to 20 bone metastases; 3) more than 20
bone metastases but less than a ‘‘superscan’’ and 4)
‘‘superscan’’ (diffuse symmetrical uptake without
visualisation of the kidneys) or its equivalent (greater
than 75% of the ribs, vertebrae and pelvic bones).
According this classification, of prostate carcinoma
patients with bone metastasis, 4 were of grade 1, 3 of
grade 2, and the remaining at grade 3.
Statistical Analysis: Differences between groups were
tested using the non-parametric Mann-Whitney U-test.
Correlations between Soloway score and parameters

Age
DPD
T-ALP
B-ALP
PSA

were calculated using Spearman’s rank correlation test. A
value of p<0.05 was regarded as significant.

Results
DPD excretion in urine was significantly greater in
prostate cancer patients with bone metastasis than in
those with to localised prostate cancer or BPH
(p<0.001), but the difference between localised the
prostate cancer and BPH groups was not significant
(p>0.05). In the prostate cancer group with bone
metastasis, although PSA values showed some overlap,
statistically significantly different mean values were
determined (Table 1). Serum markers of bone formation
(T-ALP and B-ALP) displayed higher mean concentrations
in the group with positive bone metastases than in the
group with local disease (p<0.001 for both). We
compared serum levels of T-ALP, B-ALP and PSA and
urinary DPD levels by the method of Soloway et al. for
grading bone scintigrams. Serum T-ALP and B-ALP levels
and urinary excretion of DPD were significantly
correlated with the Soloway score (p=0.03, p=0.01 and
p=0.01 respectively Table 2). However, serum PSA was
not correlated with the bone scintigram score (p=0.17).
Discussion
Prostate cancer affects mostly elderly men and bone
metastases are the most common form of prostate cancer
metastasis, the presence of which affects the prognosis of
such patients. Radioisotopic bone scans have a
remarkable sensitivity for detecting metastases, but bone
scans may not correlate with actual disease activity (7). In
addition, bone scans are expensive and incapable of
detecting bone degradation. Thus a biochemical marker
with the ability to discriminate between patients with and

BPH
(n=20)

LPC
(n=12)

MPC
(n=11)

60.5±6.52
3.73±1.60
148.85±32.34
39.30±18.74
3.57±2.70

61.75±7.82
5.19±2.32
179±44.27
46.75±28.66
8.09±4.43**

65.36±7.50
14.49±6.95*
655.27±360.83*
476.54±302.22*
197.65±107.57*

* p<0.001: MPC versus LPC and BPH; ** p<0.01: LPC versus BPH; BPH, benign prostate
hyperplasia; LPC, localised prostate cancer; MPC, metastatic prostate cancer.
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Table 1.

Median age and distribution of
values of biochemical markers in
the three groups of patients.
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Table 2.

Spearman’s rank correlation coefficients for the correlation
between Soloway grading and parameters in patients with
bone metastases.

DPD
T-ALP
B-ALP
PSA

Correlation coefficient
(r)

p

0.79
0.66
0.81
0.43

0.01
0.03
0.01
0.17

without metastatic bone involvement would be important
for the early diagnosis of advanced prostate cancer.
It is known that PSA in serum has a high diagnostic
value in the early diagnosis of prostate cancer, and it is
possible to differentiate almost completely between
patients with or without prostate cancer on the basis of
PSA measurements, but there is a considerable overlap of
PSA values between various stages of prostate cancer
(10), and decreasing levels cannot be used to evaluate
treatment efficacy in individual patients (11).
Collagen is a triple helical structure that contributes to
the strength and integrity of the bony matrix.
Degradation products of collagen are excreted in the
urine and are not reused in collagen synthesis. Recent
evidence suggests that urinary excretion of these cross-

links is not affected by dietary habits (4). Therefore,
analysis of collagen metabolites in urine has been used to
monitor bone collagen metabolism in physiological and
pathological conditions. We found that patients with bone
metastases had significantly higher mean concentrations
of urinary DPD than those of cancer patients without
clinical evidence of bone involvement. Our results
demonstrate that urinary DPD may be a clinical marker of
bone metastasis in prostate cancer, as has also been
reported by other investigators (7,12). DPD is an
analogue of pyridinoline and has a greater specificity for
bone than does pyridinoline (13).
In the present study, it was observed that T-ALP and
B-ALP can be used in diagnosing advanced prostate
cancer. The prostate cancer-related increase in serum ALP
activity is considered to reflect accelerated bone turnover
after bone metastatic prostate cancer. Our results
support the previous reports (7,12,14). In conclusion,
urinary DPD and serum B-ALP and T-ALP may provide
useful information supplementing PSA and bone-scan
results in evaluating the bone-metastatic activity.
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